ArticleBrain research2014
Chronic cannabinoid agonist (WIN 55,212-2) exposure alters hippocampal dentate gyrus spine density in adult rats.
Article in Brain research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 15 citations in OpenAlex.
- Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder.Molecular psychiatry · 2021Article
- Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.Neuropharmacology · 2021Article
- Selective effects of Δ9-tetrahydrocannabinol on medium spiny neurons in the striatum.PloS one · 2018Article
- Adolescent Exposure to the Synthetic Cannabinoid WIN 55212-2 Modifies Cocaine Withdrawal Symptoms in Adult Mice.International journal of molecular sciences · 2017Article
- Peripheral signature of altered synaptic integrity in young onset cannabis use disorder: A proteomic study of circulating extracellular vesicles.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological PsychiatryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chronic abuse of drugs can result in vast negative repercussions on behavioral and biological systems by altering underlying neurocircuitry. Long-term cannabinoid administration in rats leads to detrimental cellular and dendritic morphology changes. Previous studies have found that chronic treatment with delta-9-THC selectively decreases dendritic morphology and spine density in the dentate gyrus of adolescent rats (Rubino et al., 2009); however, whether these changes are specific to a particular developmental age is not known. The present study evaluated the effects of chronic exposure (7 or 21 days) to WIN 55,212-2 (i.p., 3.7 mg/kg), a potent cannabinoid agonist, on dendritic morphology of dentate gyrus neurons in adult rats. Upon completion of treatment brains were processed for Golgi-Cox staining. No significant effects of WIN 55,212-2 exposure were observed for dendritic branching or length. Spine density was quantified in the inner (proximal), middle, and outer (distal) thirds of the dendritic fields selected to approximate the spatial loci of afferents comprising the associational-commissural pathway, medial perforant path, and lateral perforant path, respectively. Compared to vehicle controls there was a significant reduction in spine density (~1 spine/10 μm) in the inner and middle dendritic segments. The spine density reduction was significant in inner segments following 7 days of treatment. These results suggest that chronic cannabinoid treatment specifically alters spine density in the dendritic targets of the associational-commissural afferents and medial perforant path projections, but not lateral perforant path. The resulting loss of dendritic spine density may be an important factor underlying cannabinoid induced memory impairments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.